VentriPoint Diagnostics (CVE:VPT) Reaches New 52-Week Low – Should You Sell?

VentriPoint Diagnostics Ltd. (CVE:VPT) shares hit a new 52-week low during trading on Thursday. The company traded as low as C$0.08 and last traded at C$0.08, with a volume of 63,000 shares trading hands. The stock had previously closed at C$0.09.

VentriPoint Diagnostics Stock Down 5.9%

The company has a market capitalization of C$15.43 million, a price-to-earnings ratio of -4.00 and a beta of -1.07. The firm’s 50 day moving average price is C$0.09 and its two-hundred day moving average price is C$0.11. The company has a current ratio of 0.12, a quick ratio of 6.67 and a debt-to-equity ratio of -68.25.

About VentriPoint Diagnostics

Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. It offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient’s heart chambers. The company also provides VMS+ software, a 2D and 3D ultrasound models. In addition, it develops a suite of applications for various heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging, and cardiotoxicity in oncology patients.